To be included in the trial all of the following inclusion criteria must be met:~Ability to obtain written
informed consent from the patient or caregiver as a surrogate; Meets National Institute on Aging-Alzheimer's
Association Workgroups criteria for probable AD dementia (McKhann et al. 2011); Age ≤ 80 years at time of
screening; Willing and able caregiver who has daily contact with the subject; Mini-Mental State Examination
(MMSE) score ≥ 18 and/or Clinical Dementia Rating (CDR) < 2 at the initial screening assessment; Subjects and
caregivers must be able to comply with prescribed regime of study treatment throughout the course of the study,
and meet the required time commitment of four days of in-person visits; Any concurrent treatment for AD
approved by the Food and Drug Administration (FDA), such as donepezil, galantamine, or rivastigmine, and
memantine, must be stable for at least 30 days prior to screening and at least 60 days prior to study day 1.
Other medications (except those listed under exclusion criteria) are allowed as long as the dose is stable for
30 days prior to screening.~
